Different dose-dependent correction of MIP-1β and chitotriosidase during initial enzyme replacement therapy

[1]  A. Smilde,et al.  Biomarkers for lysosomal storage disorders: identification and application as exemplified by chitotriosidase in Gaucher disease , 2008, Acta paediatrica.

[2]  C. Hollak,et al.  Increased plasma macrophage inflammatory protein (MIP)-1α and MIP-1β levels in type 1 Gaucher disease , 2007 .

[3]  C. Hollak,et al.  Monitoring of Gaucher patients with a novel chitotriosidase assay. , 2007, Clinica chimica acta; international journal of clinical chemistry.

[4]  D. Häussinger,et al.  Superior effects of high-dose enzyme replacement therapy in type 1 Gaucher disease on bone marrow involvement and chitotriosidase levels: a 2-center retrospective analysis. , 2006, Blood.

[5]  L. Boon,et al.  Gaucher cells demonstrate a distinct macrophage phenotype and resemble alternatively activated macrophages. , 2004, American journal of clinical pathology.

[6]  C. Scriver,et al.  The Metabolic and Molecular Bases of Inherited Disease, 8th Edition 2001 , 2001, Journal of Inherited Metabolic Disease.

[7]  Boris Bleijlevens,et al.  Marked elevation of the chemokine CCL18/PARC in Gaucher disease: a novel surrogate marker for assessing therapeutic intervention. , 2004, Blood.

[8]  M. Mannens,et al.  The Human Chitotriosidase Gene NATURE OF INHERITED ENZYME DEFICIENCY* , 1998 .

[9]  C. Hollak,et al.  4 Plasma and metabolic abnormalities in Gaucher's disease , 1997 .

[10]  C. Hollak,et al.  Elevated levels of M-CSF, sCD14 and IL8 in type 1 Gaucher disease. , 1997, Blood cells, molecules & diseases.

[11]  C. Hollak,et al.  Plasma and metabolic abnormalities in Gaucher's disease. , 1997, Bailliere's clinical haematology.

[12]  R. Wevers,et al.  Glucocerebrosidase genotype of Gaucher patients in The Netherlands: Limitations in prognostic value , 1997, Human mutation.

[13]  C. Hollak,et al.  Plasma tumor necrosis factor-a (TNF-a) levels in Gaucher disease. , 1996, Biochimica et biophysica acta.

[14]  P. Mistry,et al.  Therapeutic delivery of proteins to macrophages: implications for treatment of Gaucher's disease , 1996, The Lancet.

[15]  J. Aerts,et al.  Individualised low-dose alglucerase therapy for type 1 Gaucher's disease , 1995, The Lancet.

[16]  R. Schiffmann,et al.  Enzyme Therapy in Type 1 Gaucher Disease: Comparative Efficacy of Mannose-Terminated Glucocerebrosidase from Natural and Recombinant Sources , 1995, Annals of Internal Medicine.

[17]  C. Hollak,et al.  Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease. , 1994, The Journal of clinical investigation.

[18]  J. Goldblatt,et al.  Clinical phenotype of Gaucher disease in relation to properties of mutant glucocerebrosidase in cultured fibroblasts. , 1991, Biochimica et biophysica acta.

[19]  J. Dambrosia,et al.  Replacement therapy for inherited enzyme deficiency--macrophage-targeted glucocerebrosidase for Gaucher's disease. , 1991, The New England journal of medicine.

[20]  R. Van Tiggelen,et al.  Gaucher disease , 2019, Haematology.